Macintyre, A.N., Gerriets, V.A., Nichols, A.G., Michalek, R.D., Rudolph, M.C., Deoliveira, D., et al. (2014) The Glucose Transporter Glut1 is Selectively Essential for CD4 T Cell Activation and Effector Function. Cell Metabolism, 20, 61-72.
https://doi.org/10.1016/j.cmet.2014.05.004

has been cited by the following article:

• TITLE: Biological Disruptive Therapies as Counter Measures for Unpredictable Biological Insults, a Case for Successful Treatment of COVID-19

  AUTHORS: Mohammad Nezami, Vicky Yamamoto

  KEYWORDS: COVID-19, Acute Respiratory Distress Syndrome(ARDS), Phosphoinositol 3 Kinase (Pi3K), Quercetin

  JOURNAL NAME: Advances in Infectious Diseases, Vol.10 No.3, September 14, 2020

  ABSTRACT: Treatment of patients with severe COVID-19, is challenging specifically when a patient carries high risk of mortality, such as old age, immune suppression or cancer. Also a patient who manifests the disease with severe symptoms, such as hypoxia, requiring supplemental oxygenation, or artificial ventilation has a poor prognosis. Here we review the scientific rationale used to design a very promising therapy based on existing literature, but in significantly different method and protocols, used to treat cases of severe COVID-19, and we conclude that although the effort on drug development has been enormous, but as of today, we do not have a therapy with specific characteristics as this protocol, to be used safely in human and yet potentially meet the expectations we would have for a so called “effective therapy”. Further clinical trials are needed to support this hypothesis and generate further hypothesis to prove the concept in larger cohort of patients.